https://www.frontierspartnerships.org/journals/journal-of-pharmacy-pharmaceutical-sciences RSS Feed for Journal of Pharmacy & Pharmaceutical Sciences | New and Recent Articles en-us Frontiers Feed Generator,version:1 2026-04-19T22:17:42.322+00:00 60 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16294 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16294 2026-04-15T00:00:00Z Original Research Madhuri BudamkayalaJyostna YalakalaMadison B. SkeenSurya KaruturiChelsey McPhillenKristen BaileyTodd H. DaviesMichael D. Hambuchen https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16123 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16123 2026-03-26T00:00:00Z Original Research Liang JuanChih-Ning ChengWen-Chi ChangHuai-Hsuan ChiuChao-Wen LuHsao-Hsun HsuChing-Hua KuoYu-Ju Tseng 0.99) and accuracy within 85–115% across validation ranges (10–20,000 ng/mL for MPA; 0.5–500 ng/mL for TAC). Formula A-ind [(VAMS/1 – individual Hct) x fbpp], where fbpp represents the MPA protein binding fraction (0.97), achieved clinical agreement in 86% of samples for the conversion of MPA concentrations between VAMS and plasma, representing the most balanced between predictive reliability and operational feasibility. TAC concentrations from VAMS correlated strongly with whole blood values without requiring Hct correction. Clinical case applications showed that rich eight-point VAMS sampling enabled more accurate AUC estimations than conventional three-point schemes, further highlighting the advantages of using VAMS for MPA TDM.ConclusionThis validated VAMS-based approach offers a minimally invasive and clinically applicable alternative to venous sampling for MPA and TAC monitoring. Incorporating individualized Hct adjustments improves predictive performance, supporting conditional integration of VAMS into routine TDM.]]> https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16155 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16155 2026-03-11T00:00:00Z Original Research Sarah RezaziCherif Si-MoussaSalah Hanini https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.15679 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.15679 2026-03-05T00:00:00Z Original Research Marius Călin CherecheşAura Rusu https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16236 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16236 2026-03-04T00:00:00Z Special Issue Editorial Allison WillsCatherine Y. Lau https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.15714 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.15714 2026-03-04T00:00:00Z Mini Review Joseph CorreaNicole K. Brogden 80% of asthma patients also suffer from allergies), and pharmacological treatment is the cornerstone for acute exacerbations and ongoing maintenance. Typical treatment options for asthma include inhaled, oral, or injectable dosage forms. However, transdermal drug delivery has great potential to provide an alternative route of administration of necessary asthma and allergy therapies that have traditionally been given in other dosage forms. In Part 1 of this two-part series, we discussed the work done towards incorporating short- and long-acting β2-agonists into transdermal drug delivery systems. Here in part 2, we describe the current literature for transdermal applications of leukotriene antagonists, theophylline, and other adjunct medications that do not fall into one specific drug class. A brief overview of biologics, particularly monoclonal antibodies, and the role in asthma is also included, including some context of transdermal mAb delivery for disease states beyond asthma. Because of the relatedness of asthma and allergies, transdermal applications for allergen immunotherapy is also discussed.]]> https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.15713 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.15713 2026-03-04T00:00:00Z Mini Review Joseph CorreaNicole K. Brogden https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.15563 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.15563 2026-02-17T00:00:00Z Correction Sunbeom KwonSuji JeongSeulah Lee https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.15721 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.15721 2026-02-13T00:00:00Z Original Research Nasim SarramiSoheyla HonaryMohammad Reza VakiliAfsaneh Lavasanifar https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15403 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15403 2026-01-13T00:00:00Z Review Haider Hamzah https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15678 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15678 2026-01-12T00:00:00Z Original Research Rui XuHui PengChang ShuMaochang LiuPing Gao https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15597 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15597 2026-01-07T00:00:00Z Original Research Yan WangLiu-Yi-Yi YangYa-Gang Zuo nivolumab > tislelizumab > pembrolizumab > ipilimumab > durvalumab > atezolizumab > avelumab. The median time of irBP onset was 165.2 (IQR: 56–410) days.ConclusionThe study establishes a significant link between ICIs and BP. All ICIs increase BP risk. CTLA-4 inhibitors exhibited the most marked early risk concentration, highlighting the importance of early dermatologic evaluation after initiating CTLA-4 blockade.]]> https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15525 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15525 2026-01-07T00:00:00Z Original Research Nader I. NamaziRawan BafailAbdulkareem Ali AlaneziAfaf F. AlmuqatiMohammed Salem AlshammariMajed A. Alghamdi https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15360 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15360 2026-01-06T00:00:00Z Review Aashirwad ShahiShengyuan ZhaoDawit Kidane https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15527 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15527 2025-12-16T00:00:00Z Original Research Yonghoon KwonNai LeeYun Kim 1 and at least three unique cases. Subgroup analyses were conducted by pregnancy status and underlying autoimmune indications, and comparative analyses were performed against drugs previously reported to induce ICP.ResultsAmong 35,576 AZA-related reports, 67 specifically documented ICP. A strong signal was detected for ICP ROR025 = 153.0; IC025 = 5.8; EBGM05 = 144.37), ranking among the highest AZA-associated adverse events. In pregnant women, ICP also showed a significant signal (ROR025 = 5.46; IC025 = 1.93; EBGM05 = 5.31). Subgroup analyses by indication revealed elevated risks in Crohn’s disease (ROR025 = 66.99; IC025 = 4.8; EBGM05 = 64.73), and Colitis ulcerative (ROR025 = 9.01; IC025 = 1.95; EBGM05 = 9.95). Comparative analyses demonstrated that AZA had a higher proportion of ICP cases than other drugs reported to induce ICP.ConclusionThis pharmacovigilance analysis identifies a disproportionality signal suggesting a possible association between AZA and intrahepatic cholestasis of pregnancy. These hypothesis-generating findings underscore the importance of cautious use and clinical vigilance when prescribing AZA to women of reproductive age.]]> https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15688 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15688 2025-12-04T00:00:00Z Brief Research Report Tanin ShafaatiAmanda A. GreenwellChristina T. SaedSeyed Amirhossein Tabatabaei DakhiliJordan S. F. ChanLinyue DongMagnus J. StenlundSally R. FerrariRuth HanJennifer KrugerFarah EatonKeshav GopalSandra T. DavidgeGavin Y. OuditJohn R. Ussher https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15387 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15387 2025-12-02T00:00:00Z Original Research Laura DuboisCyrielle BouguergourRomain Paoli-LombardoCaroline Castera-DucrosChristophe JeanMélanie FuchsPatrice VanellePascal RathelotThierry TermeChristophe Curti https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15249 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15249 2025-12-01T00:00:00Z Original Research Faten AlhomoudSakinah AlalwyatLama AlanziFarah Kais AlhomoudSarah KhayyatKhalid A. AlamerBasmah AlfagehMohra AladwaniAbdullah A. Alhifany https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.14880 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.14880 2025-11-27T00:00:00Z Original Research Jean Baptiste NyandwiPierre Celestin MunezeroCharles UwambajimanaGift Crucifix PenderJonathan KatandulaThéoneste UmumararunguJean Paul SinumvayoIbrahim Eleha SuleimanTolessa Muleta DabaVedaste KagishaMarie Françoise MukanyangeziAhmed Adebowale Adedeji https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15310 https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15310 2025-11-19T00:00:00Z Original Research Laurie DezStéphane HaÿsGilles LeboucherRomain GarreauJean-Charles PicaudThomas Briot